Propranolol dosing, duration and outcome in infantile haemangiomas
| Author | Country of study | Number of patients | Dose range (mg/kg/day) | Age range (median, months) at initiation (months) | Location of haemangioma | Duration of treatment (months) | Outcome |
|---|---|---|---|---|---|---|---|
| Buckmiller et al6 | USA | 41 | 2 | 1.5–30 (7.1) | Multiple sites | Not reported | 16 excellent responders 15 partial responders 1 non-responder |
| Leaute-Labreze et al7 | France | 11 | 2–3 | 2–6 (3.2) | Facial: 10 Forearm: 1 | 4–12 | All regressed or stabilised |
| Sans et al8 | France | 32 | 2–3 | 2–41 (4.2) | Multiple sites | 3–10 | 10 regressed 6 mild relapse 9 treatment ongoing |
| Denoyelle et al9 | France | 2 | 2–3 | 4 and 11 | Phaces: 1 Subglottic: 1 | 7 | Both responded with no regression |
| Rosbe et al10 | USA | 3 | 1–2 | 3 weeks–8 months (4.9) | Subglottic | 7–18 | 2 completely responded |
| Marsciani et al11 | Italy | 1 | 1–2 | 2 | Hepatic | Not reported | Excellent response |
| Li et al12 | Australia | 4 | 2 | 11 weeks–2.5 years (10.5) | Orbital | 6–12 months | All improved |
| Manunza et al13 | UK | 30 | 2 | 1.2–13.5 (5.8) | Facial | 3.5–15 | All improved |
| Haider et al14 | USA | 17 | Initially 0.5, increased slowly to 2 | 3 weeks–12 months | Periocular | Until resolution or 9–11 months of age | 10 excellent responders 6 good response 1 fair response |
| Maturo et al15 | USA | 2 | 2 | 3 and 5 | Airway | Not reported | Both responded |
| Nauouri et al16 | France | 4 | 1–2 | 5 weeks–5 months (3.0) | UlceratedLip: 1 Body: 2 Skull: 1 | 92 ongoing treatment | 3 excellent response 1 relapsed off treatment |
| Qin et al17 | China | 58 | 1–1.5 | 1–12 (4) | Multiple | 2–5 | 10 excellent response 35 good response 12 moderate response 1 poor response |